P<sub>1</sub>PK血型抗原研究进展

范春丽; 李树中; 李中华; 叶小英; 胡氏月; 李凌波

doi:10.13201/j.issn.1004-2806-b.2018.08.022

P₁PK血型抗原研究进展

- 1. 江苏大学附属昆山第一人民医院(江苏昆山, 215300);
- 2. 黑龙江省牡丹江市第二人民医院;
- 3. 长春博讯生物技术有限责任公司

详细信息

通讯作者: 李树中:E-mail:kssyylsz@sina.cn

中图分类号: R392.11

收稿日期: 2018-03-27

Research progress of P₁PK blood group antigen

More Information

Corresponding author: , E-mail: kssyylsz@sina.cn

Received Date: 27 March 2018

摘要

- 糖苷类抗原 /
- 副糖苷类抗原 /
- 冷抗体 /
- 自身抗体
Abstract: In 2011,ISBT reconfirmed three antigens of P1PK blood group system and clarified the definition of related antigens.The three antigens of the P1Pk blood group belong to the paracosides and glycoside antigens respectively.It has been confirmed that the gene of this antigen is A4GALT and three exon sequences,and the encoded glycosyltransferase has 353amino acids.Gene mutations occur mainly in exon 3.P1PK blood group antibodies have cold antibodies and autoantibodies,individual can cause hemolysis.This article describes the latest research progress of the antigen,and clarifies some past mistakes and vague understanding.
- glycoside antigen /
- paranoside antigen /
- cold antibody /
- autoantibody

HTML全文

参考文献(35)

[1]	Garraud O,Cognasse F,Tissot JD,et al.Improving platelet transfusion safety:biomedical and technical considerations[J].Blood Transfus,2016,14:109-122.
[2]	Ness PM,Campbell-Lee SA.Single donor versus pooled random donor platelet concentrates[J].Cur Opin Hematol,2001,8:392-396.
[3]	van der Meer PF,Gulliksson H,Aubuchon JP,et al.Interruption of agitation of platelet concentrates:effects on in vitro parameters[J].Vox Sang,2005,88:227-234.
[4]	Krailadsiri P,Seghatchian J.Are all leucodepleted platelet concentrates equivalent?Comparison of Cobe LRS Turbo,HaemoneticsMCS+LD,and filtered pooled buffy-coat-derived platelets[J].Vox Sang,2000,78:171-175.
[5]	Goodrich RP,Li J,Pieters H,et al.Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects[J].Vox Sang,2006,90:279-285.
[6]	Heddle NM,Arnold DM,Boye D,et al.Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions[J].Transfusion,2008,48:1447-1458.
[7]	Schiffer CA,Lee EJ,Ness PM,et al.Clinical evaluation of platelet concentrates stored for one to five days[J].Blood,1986,67:1591-1594.
[8]	Leach MF,AuBuchon JP.Effect of storage time on clinical efficacy of single-donor platelet units[J].Transfusion,1993,33:661-664.
[9]	Anderson NA,Gray S,Copplestone JA,et al.A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy:corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions[J].Transfus Med,1997,7:33-39.
[10]	Slichter SJ,Kaufman RM,Assmann SF,et al.Dose of prophylactic platelet transfusions and prevention of hemorrhage[J].N Engl J Med,2010,362:600-613.
[11]	Triulzi DJ,Assmann SF,Strauss RG,et al.The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia[J].Blood,2012,119:5553-5562.
[12]	Kuehnert MJ,Roth VR,Haley NR,et al.Transfusion-transmitted bacterial infection in the United States,1998 through 2000[J].Transfusion,2001,41:1493-1499.
[13]	Lafeuillade B,Eb F,Ounnoughene N.et al.Residual risk and retrospective analysis of transfusion-transmitted bacterial infection reported by the French National Hemovigilance network from 2000 to 2008[J].Transfusion,2015,55:636-646.
[14]	Dykstra A,Hoeltge G,Jacobs M,et al.Platelet bacterial contamination (PBC) rate is surveillance method (SM) dependent[J].Transfusion,1998,38:104s.
[15]	Jacobs MR,Good CE,Lazarus HM,et al.Relationship between bacterial load,species virulence,and transfusion reaction with transfusion of bacterially contaminated platelets[J].Clin Infect Dis,2008,46:1214-1220.
[16]	Vamvakas EC.Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States:a systematic review of disparate risks[J].Transfusion,2009,49:2743-2758.
[17]	Jacobs MR,Smith D,Heaton WA,et al.Detection of bacterial contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera Detection test[J].Transfusion,2011,51:2573-2582.
[18]	Harm SK,Delaney M,Charapata M,et al.Routine use of a rapid test to detect bacteria at the time of issue for nonleukoreduced,whole blood-derived platelets[J].Transfusion,2013,53:843-850.
[19]	Blajchman MA,Goldman M,Baeza F.Improving the bacteriological safety of platelet transfusions[J].Transfus Med Rev,2004,18:11-24.
[20]	Offergeld R,Ritter S,Kamp C,et al.Differences in infection risks between pool and apheresis platelets-a mathematic model[J].Transfus Med Hemother,2012,39:3-5.
[21]	an der Heiden M,Ritter S,Hamouda O,et al.Estimating the residual risk for HIV,HCV and HBV in different types of platelet concentrates in Germany[J].Vox Sang,2015,108:123-130.
[22]	Butler C,Doree C,Estcourt LJ,et al.Pathogen-reduced platelets for the prevention of bleeding[J].Cochrane Database Syst Rev,2013,28:CD009072.
[23]	The Trial to Reduce Alloimmunization to Platelets Study Group.Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions[J].New Eng J Med,1997,337:1861-1869.
[24]	Hess JR,Trachtenberg FL,Assmann SF,et al.Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial[J].Vox Sang,2016,111:281-291.
[25]	Cid J,Carbasse G,Pereira A,et al.Platelet transfusions from D+donors to D patients:a 10-year follow-up study of 1014 patients[J].Transfusion,2011,51:1163-1169.
[26]	Cid J,Lozano M,Ziman A,et al.Low frequency of anti-D alloimmunization following D+platelet transfusion:the Anti-D Alloimmunization after D-incompatible Platelet Transfusions (ADAPT) study[J].Br J Haematol,2015,168:598-603.
[27]	Cid J,Yazer MH,Lozano M.Platelet transfusion and respecting patient D type[J].Cur Opin Hematol,2015,22:540-546.
[28]	Shaz BH,Hillyer CD.Residual risk of D alloimmunization:is it time to feel safe about platelets from D+donors?[J].Transfusion,2011,51:1132-1135.
[29]	Eder AF,Herron R,Strupp A,et al.Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross[J].Transfusion,2007,47:599-607.
[30]	Eder AF,Herron RM Jr,Strupp A,et al.Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008)[J].Transfusion,2010,50:1732-1742.
[31]	Robillard P,Hyson C,Mc Combie N.TRALI,possible TRALI and respiratory complications of transfusion reported to the Canadian Transfusion-Transmitted Injuries Surveillance System[J].Transfusion,2007,47:5A-6A.
[32]	Gajic O,Rana R,Winters JL,et al.Transfusion-related acute lung injury in the critically ill:prospective nested case-control study[J].Am J Respir Crit Care Med,2007,176:886-891.
[33]	Ferrer F,Rivera J,Corral J,et al.Evaluation of pooled platelet concentrates using prestorage versus poststorage WBC reduction:impact of filtration timing[J].Transfusion,2000,40:781-788.
[34]	Kaufman RM,Assmann SF,Triulzi DJ,et al.Transfusion-relatedadverse events in the Platelet Dose study[J].Transfusion,2015,55:144-153.
[35]	XiaoW,Tormey CA,Capetillo A,et al.Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components[J].Vox Sang,2013,105:334-340.